-
公开(公告)号：US20190352388A1
公开(公告)日：2019-11-21
申请号：US16415231
申请日：2019-05-17
Applicant: Janssen Biotech, Inc.
Inventor： Matteo Cesaroni , Matthew Loza , Jarrat Jordan , Loqmane Seridi
IPC: C07K16/24 , A61K9/00 , A61P37/06 , C12Q1/6883
Abstract: Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.
-
公开(公告)号：US10155809B2
公开(公告)日：2018-12-18
申请号：US15707317
申请日：2017-09-18
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
Abstract: Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω.
-
公开(公告)号：US12202892B2
公开(公告)日：2025-01-21
申请号：US16839249
申请日：2020-04-03
Applicant: Janssen Biotech, Inc.
Inventor： Marc Chevrier , Jarrat Jordan
IPC: A61K39/395 , A61K47/12 , A61K47/26 , A61P37/02 , C07K16/24 , A61K9/00 , A61K31/4706 , A61K31/519 , A61K31/573 , A61K39/00
Abstract: Methods for administration of an anti-IFN-α/-ω antibody by subcutaneous or intravenous administration in a clinically proven safe amount are provided. Also provided are methods for clinically proven safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE), by subcutaneous or intravenous administration of an anti-IFN-α/-ω antibody.
-
公开(公告)号：US12009079B2
公开(公告)日：2024-06-11
申请号：US16663527
申请日：2019-10-25
Applicant: Janssen Biotech, Inc.
Inventor： Matteo Cesaroni , Marc Chevrier , Jarrat Jordan , Jessica Schreiter
IPC: C07K14/56 , C12Q1/6809 , G16H20/10 , G16H50/30
CPC classification number: G16H20/10 , C07K14/56 , C12Q1/6809 , G16H50/30 , C07K2317/565 , C12Q2539/00 , C12Q2545/114
Abstract: Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.
-
公开(公告)号：US11578124B2
公开(公告)日：2023-02-14
申请号：US16415231
申请日：2019-05-17
Applicant: Janssen Biotech, Inc.
Inventor： Matteo Cesaroni , Matthew Loza , Jarrat Jordan , Loqmane Seridi
IPC: C07K16/24 , A61K9/00 , A61P37/06 , G01N29/44 , G01N33/483 , G01N33/564 , C12Q1/6883 , A61K39/00
Abstract: Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.
-
Patent Agency Ranking
公开(公告)号：US10759854B2
公开(公告)日：2020-09-01
申请号：US16424907
申请日：2019-05-29
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
IPC: C07K16/24 , A61K38/13 , A61K45/06 , A61K39/395 , A61K39/00
Abstract: The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US20230279097A1
公开(公告)日：2023-09-07
申请号：US18154116
申请日：2023-01-13
Applicant: Janssen Biotech, Inc.
Inventor： Matteo Cesaroni , Matthew Loza , Jarrat Jordan , Loqmane Seridi
IPC: C07K16/24 , G01N33/483 , G01N29/44 , C12Q1/6883 , A61K9/00 , A61P37/06 , G01N33/564 , A61K39/00
CPC classification number: C07K16/244 , G01N33/483 , G01N29/4418 , C07K16/249 , C12Q1/6883 , A61K9/0019 , A61P37/06 , G01N33/564 , C07K2317/21 , A61K2039/505 , C12Q2600/158 , C12Q2600/106 , G01N2333/555 , A61K2039/545 , C07K2317/76
Abstract: The present invention relates to methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20190135912A1
公开(公告)日：2019-05-09
申请号：US16184270
申请日：2018-11-08
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
IPC: C07K16/24
Abstract: Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are usefule in the treatment of diseases associated with increased production of IFNα and IFNω.
-
公开(公告)号：US20190106489A1
公开(公告)日：2019-04-11
申请号：US16222285
申请日：2018-12-17
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
CPC classification number: C07K16/249 , A61K38/13 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US20190359705A1
公开(公告)日：2019-11-28
申请号：US16424907
申请日：2019-05-29
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
Abstract: The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.021 seconds)
